Tiziana Life Sciences (TLSA) announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis, ECTRIMS, being held September 24-26, 2025, in Barcelona, Spain. The poster, titled “Study Design of a Phase 2a Double-Blind Placebo-Controlled Trial of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis,” will outline the clinical trial design and objectives for Tiziana’s innovative nasal foralumab program. Nasal foralumab is the first entirely human anti-CD3 monoclonal antibody designed for intranasal delivery, representing a novel approach to modulating the immune system for the treatment of non-active secondary progressive multiple sclerosis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Secures DoD Grant for Spinal Cord Injury Research
- Tiziana Life Sciences announces U.S. DoD awarded research grant to study SCI
- Tiziana Life Sciences CEO Increases Stake Amidst Ongoing Clinical Trials
- Tiziana Life Sciences reports CEO purchased 14,848 shares
- Tiziana Life Sciences CEO Buys Shares, Signaling Confidence in Innovative Therapies